|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00018382 |
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.
Condition | Intervention | Phase |
Alzheimer Disease |
Drug: rosiglitazone |
Phase II |
Genetics Home Reference related topics: | Alzheimer disease |
MedlinePlus related topics: | Alzheimer's Disease Memory |
Drug Information available for: | Insulin Rosiglitazone Rosiglitazone Maleate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
Official Title: | Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach |
Ages Eligible for Study: | 55 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.
United States, Washington | |||||
VA Puget Sound Health Care System | |||||
Seattle, Washington, United States, 98108 |
Investigator: | Steven Kahn, M.D. | |
Investigator: | Sanjay Asthana, M.D. | |
Investigator: | Alfred Fujimoto, M.D. |
Study ID Numbers: | AGCG-012-98S |
First Received: | July 3, 2001 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00018382 |
Health Authority: | United States: Federal Government |
|
|
|